Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
- E. Thiele, E. Marsh, A. Wilfong
- Medicine, PsychologyThe Lancet
- 17 March 2018
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
- O. Devinsky, Anup D. Patel, K. Sommerville
- MedicineNeurology
- 3 April 2018
This study provides Class I evidence that for children with Dravet syndrome, CBD resulted in more AEs than placebo but was generally well-tolerated.
A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.
- J. Zajecka, R. Weisler, G. Sachs, A. Swann, P. Wozniak, K. Sommerville
- Psychology, MedicineJournal of Clinical Psychiatry
- 1 December 2002
Divalproex was associated with a more favorable adverse event profile and significantly less weight gain than olanzapine and a number of laboratory measures also demonstrated significant treatment differences, but the clinical significance of many of these is uncertain.
A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
- Gilmour Morrison, Julie Crockett, G. Blakey, K. Sommerville
- Biology, MedicineClinical pharmacology in drug development
- 21 February 2019
Cannabidiol was moderately well tolerated, with similar incidences of adverse events reported when coadministered with clobazam, stiripentol, or valproate, and when co Administered with each antiepileptic drug.
Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia
- D. Casey, D. Daniel, A. Wassef, Latherine A Tracy, P. Wozniak, K. Sommerville
- Psychology, MedicineNeuropsychopharmacology
- 2003
Treatment with divalproex in combination with an atypical antipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutely hospitalized patients with schizophrenia.
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations
- R. Dworkin, D. Turk, D. Ziegler
- MedicinePain
- 1 June 2012
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.
- W. Oertel, H. Benes̆, K. Stiasny‐Kolster
- Medicine, PsychologySleep Medicine
- 1 March 2008
A double-blind, placebo-controlled study of Vigabatrin three g/day in patients with uncontrolled complex partial seizures
- J. French, M. Mosier, S. Walker, K. Sommerville, N. Sussman
- Medicine, PsychologyNeurology
- 1 January 1996
It is indicated that 3 g/day vigabatrin is more effective than placebo as add-on therapy in patients with focal epilepsy whose complex partial seizures were difficult to control with established antiepilepsy drug therapy.
Divalproex in the Treatment of Impulsive Aggression: Efficacy in Cluster B Personality Disorders*
- E. Hollander, Katherine A. Tracy, C. Nemeroff
- PsychologyNeuropsychopharmacology
- 2003
While a treatment effect was not observed when all diagnostic groups were combined, in a large subgroup of patients with Cluster B disorders, divalproex was superior to placebo in the treatment of impulsive aggression, irritability, and global severity.
Effects of Tiagabine Monotherapy on Abilities, Adjustment, and Mood
- C. Dodrill, J. Arnett, V. Shu, G. Pixton, G. Lenz, K. Sommerville
- PsychologyEpilepsia
- 1 January 1998
The dose‐related impacts of tiagabine (TGB) on cognition and mood in a monotherapy study found no significant differences in cognition or mood between the two groups.
...
...